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Introduction
In our recent review we described the deep change obtained in the
management of breast cancer (BC) over the last decade using
combinations of different types of treatment [1]. Better knowledge of
oncogenesis, biological characteristics of different types of cancer and
the introduction of new drugs have identified possible combinations to
overcome the multiple mechanisms of resistance put in place by tumor
cells to achieve proliferation and progression.
Given the important and increasingly encouraging results obtained
with immunological therapies, particularly in the treatment of
melanoma [2-6], non-small cell lung carcinoma (NSCLC) [7], and
renal cell carcinoma (RCC) [8], we considered necessary to contribute
with a brief comment about these new therapeutic approaches and
their possible role in the management of BC, particularly as a
combination strategy.
The understanding of the so called "immune checkpoints”, capable
of regulating T-cell suppression, has led to the development of immune
checkpoint inhibitors for cancer treatment. Nowadays the better
known immune checkpoint inhibitors are represented by the blocking
antibody (Ab) against T-Lymphocyte-associated-protein-4 (CTLA-4),
the Abs against programmed death-1 (PD-1) and the Ab against
programmed death-ligand-1 (PD-L1).
CTLA-4 expression is induced in activated T-cell, it competes with
CD28 receptor binding CD80 and CD86 with approximately 100-fold
greater affinity than the CD28 receptor, and leads to a reduction of T-
cell population therefore; CTLA-4 downregulates T-cell function. As a
confirmation of the T-cells function suppression induced by CTLA-4,
mice deficient in CTLA-4 die from fatal lymphoproliferation [9,10].
The inhibition of CTLA-4 involves the loss of control on T-cells
determining cancer cells death and antitumor immunity. Ipilimumab
(Yervoy®, Bristol Myers Squibb, Princeton, NJ) was the first anti-
CTLA-4 Ab clinically approved after the milestone trials that showed a
significant improvement in overall survival (OS) for patients with
metastatic melanoma [2,3].
PD-1 is expressed on antigen-experienced memory T-cells in
peripheral tissues; when PD-1 is engaged by its ligands, PD-L1 and
PD-L2, it inhibits T-cell activation thus resulting in a negative
regulation of T-cell activity. PD-1 is also expressed on B-cells,
monocytes, dendritic cells and NK cells therefore, blockade of the
PD-1 pathway may influence the function of these cell as well [11]. The
preclinical rationale that inhibition of PD-1 could lead to antitumor
activity mediated by the immune system was confirmed by the phase
III clinical trials in different solid tumors such as melanoma, NSCLC
and RCC. Nivolumab (Opdivo®, Bristol-Myers Squibb, Princeton, NJ)
is an IgG4 fully human anti-PD-1 Ab recently approved for the
treatment of metastatic melanoma, NSCLC and RCC [5,7,8], and
Pembrolizumab (Keytruda®, Merck, Darmstadt, Germany) is an IgG4
engineered humanized anti-PD-1 Ab approved for the treatment of
metastatic melanoma and NCSLC [6,12].
PD-L1 is expressed on many cell types, including T-cells, B-cells,
monocytes, antigen-presenting cell and epithelial cells. PD-L1 is
believed to exert negative signals on T-cells not only by binding PD-1
but also by interacting with B7, expressed on dendritic cells [13].
Atezolizumab (MPDL3280A, Roche) is an IgG4 engineered fully
human anti-PD-L1 Ab that doubled OS compared with docetaxel in
previously treated patients with PD-L1-positive NSCLC, according to
results from the phase II POPLAR study and BIRCH trial [14,15].
In BC the presence of lymphocytic infiltrates as possible prognostic
factor was evaluated decades ago. Recently, tumor-infiltrating
lymphocytes (TILs) are described as a prognostic factor in Triple
Negative Breast Cancer (TNBC). Indeed, Loi et al. demonstrated the
association between TILs and better outcomes in this BC subtype
evaluating data from the BIG 02-98 trial [16]. In particular, the
increment in stromal and intratumoral lymphocytic infiltrations is
correlated with the reduction of risk of death. These data were
confirmed by Adams et al. that evaluated the correlation between TILs
and prognosis in two large phase III clinical trials: ECOG 2197 and
ECOG 1199. The authors demonstrated that stromal TILs are an
independent prognostic factor for disease free survival (DFS), distant
recurrence–free interval (DRFI) and OS [17]. It is important to
underline that all these results concern the adjuvant setting and
encourage further evaluations to standardize a definition of TILs that
could be included in the routine histopathological examination.
Confirming the critical role of the immune system in TNBC, an
interesting work by Burstein et al. explored TNBC molecular
phenotypes using RNA gene expression profiling and described four
subtypes of these tumors: Luminal Androgen Receptor (LAR),
Mesenchymal (MES), Basal Like Immune-Suppressed (BLIS) and Basal
Like Immune-Activated (BLIA). A correlation between these
molecular phenotypes and clinical features shows that BLIS subtype
has a significantly poorer prognosis in terms of DFS and Disease
Specific Survival (DSS) versus all subtypes and conversely the BLIA
subtype present the best results in terms of DFS and DSS [18]. These
data further support the importance of the immune system in the
control of tumor growth and progression. Therefore, Ab anti-CTLA-4,
Ab anti-PD1 and Ab anti-PDL1 could represent a new effective
treatment option in the management of BC. Different studies have
demonstrated a positive correlation between CTLA-4, PD-1 and PD-
L1 with increase in TILs and improved outcomes [19-22]. The
checkpoint inhibitors Pembrolimzumab and Atezolizumab were
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evaluated in phase I studies in TNBC [23,24]. In the KEYNOTE-012
trial, approximately 56% of patients treated with Pembrolizumab
experienced a treatment-related adverse event (AE), including fatigue,
arthralgia, myalgia, and headache. One patient died of disseminated
intravascular coagulation, which was attributed to the immunotherapy.
The Overall Response Rate (ORR) was 18.5% with 1 complete and 4
partial responses. Seven patients had stable disease. Furthermore the
phase I trial with Atezolizumab showed that between the 12 patients
assessed for safety endpoints, 1 patient experienced grade 3-4 adrenal
insufficiency; between the 9 patients assessed for response to therapy,
ORR was 33%. Both treatments show activity in this subtype of BC,
therefore further trials are investigating these molecules in successive
phases of study.
A possible strategy to obtain improved outcomes in terms of DFS
and OS is the combination of these immune checkpoint inhibitors with
chemotherapy and/or hormonal-therapies. It is worth noting that
many chemotherapeutic agents are immunogenic and this could
implement the immunotherapeutic effect of checkpoint inhibitors [25].
This concept is reinforced by the fact that chemotherapy is not only
immunogenic but also capable to determine significant responses in
terms of DFS and OS, responses that could be improved by the
combination with immunotherapies [26]. Furthermore, the association
between hormonal-therapies and immunotherapies could be active in
luminal BC. In this BC subtype the preliminary results of the
KEYNOTE-028 trial were presented at the 2015 San Antonio Breast
Cancer Symposium [27] and showed activity of Pembrolizumab also in
Estrogen receptor positive (ER+)/HER2 negative BCs. Also Avelumab,
another Ab anti-PD-L1, demonstrated to be active in a phase I trial in
which responses were observed in all subtypes of BC [28].
Advances in the understanding of the interaction between the
immune system and tumor cells have also contributed to the
development of other therapeutic strategies based on chimeric antigen
receptor (CAR) modified T cells or NK cells. The classic CARs T cells
consist of an extracellular antigen recognition domain, a hinge
domain, a transmembrane domain and an intracellular domain [29].
The extracellular antigen-binding moiety renders T cells the ability to
bind antigens with retained specificity and affinity [30]. The hinge
region mediates CAR flexibility [31] and the transmembrane can
indeed influence the function of CAR-T cells [32]. The intracellular
domain is responsible for signal delivery within CARs. CAR-T cell
immunotherapy demonstrated remarkable clinical responses in
hematologic malignancies [33] and now it could represent an
interesting challenge in solid tumors treatment. At the same time,
given their shorter lifespan and potent cytolytic function, mature NK
cells provide attractive candidate effector cells to express CARs and
provide an excellent source of therapy for patients with cancer [34].
Another important observation is that the escape from host
immunosurveillance resulting in cancer growth and progression
depends from different alterations in immune response like the
enhancement of immunosuppressive cells such as myeloid-derived
suppressor cells (MDSCs). Several approaches to obtain suppression of
MDSCs have been sought after [35].
The use of CAR-T or CAR-NK cells and suppression of MDSCs may
enhance and sensitize the effects of chemotherapies and checkpoints
inhibitors in solid tumors and particularly in BC. Nevertheless more
data are still needed to better apply CAR-T, CAR-NK cells and MDSCs
techniques in treating solid tumors.
All these data represent the background for a new era in BC
management. As we have seen in our precedent review, combination of
different types of treatment is an important strategy to overcome
cancer resistance and proliferation. Therefore, combination of new
molecules with “classic” therapies, such as chemotherapy and
hormonal-therapy, could become the new standard for BC treatment.
Further clinical trials are warranted to confirm this interesting
hypothesis.
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